|
Main
|
|
Note: This record shows only the 20 elements of the WHO Trial Registration Data Set. To view changes that have been made to the source record, or for additional information about this trial, click on the URL below to go to the source record in the primary register. |
|
Register:
|
ClinicalTrials.gov |
|
Last refreshed on:
|
17 October 2012 |
|
Main ID: |
NCT00932269 |
|
Date of registration:
|
30/06/2009 |
|
Primary sponsor: |
|
|
Public title:
|
Seroimmunity 2007 and Sub Study of the Swedish Population Regarding Vaccine Preventable Disease
Sero 2007 |
|
Scientific title:
|
Seroimmunity 2007. Serological Study of the Swedish Population Regarding Vaccine Preventable Diseases Within the National Immunization Program (NIP), and a Sub Study Focusing on Foreign Born 14-16 Year-Olds. |
|
Date of first enrolment:
|
March 2007 |
|
Target sample size:
|
5400 |
|
Recruitment status: |
Active, not recruiting |
|
URL:
|
http://clinicaltrials.gov/show/NCT00932269 |
|
Study type:
|
Observational |
|
Study design:
|
Observational Model: Cohort, Time Perspective: Cross-Sectional
|
|
|
Countries of recruitment
|
|
Sweden
| | | | | | | |
|
Contacts
|
|
Name:
|
Eva Netterlid |
|
Address:
|
|
|
Telephone:
|
|
|
Email:
|
|
|
Affiliation:
|
Swedish Institute for Infectious Disease Control |
|
|
Name:
|
Rigmor Thorstensson, Assoc. Prof. |
|
Address:
|
|
|
Telephone:
|
|
|
Email:
|
|
|
Affiliation:
|
Swedish Institute for Infectious Disease Control |
| |
|
Key inclusion & exclusion criteria
|
Inclusion Criteria:
- informed written consent (both groups)
- immigrated to Sweden after 6 years of age from a country with polio vaccination
coverage < 85 % (Sub study group)
- living and attending school in Stockholm, Gothenburg or Malmoe (Sub study group)
Age minimum:
N/A
Age maximum:
N/A
Gender:
Both
|
|
Health Condition(s) or Problem(s) studied
|
|
Diphtheria
|
|
Haemophilus Influenzae Type B
|
|
Hepatitis B
|
|
Measles
|
|
Mumps
|
|
Pertussis
|
|
Polio
|
|
Rubella
|
|
Tetanus
|
|
Primary Outcome(s)
|
|
Establishing the immunity situation among specific population groups, concerning diseases targeted by the NIP, by measuring antibody levels in serum using methods In-house ELISAs, Neutralization test (NT) and ELISAs from Dade Behring
[Time Frame: 3 years]
|
|
Secondary Outcome(s)
|
|
To confirm the protection against polio among the Swedish population by measuring antibody levels in serum using NT against Polio virus types 1-3
[Time Frame: 3 years]
|
|
Secondary ID(s)
|
|
2007/132-31/4//2008/164-32
|
|
Source(s) of Monetary Support
|
|
Please refer to primary and secondary sponsors
|
|